Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines Proxygen’s unique molecular glue degrader discovery platform and its expertise in targeted protein degradation with Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough therapies for cancer patients.
This text is a press release from Proxygen. The full text version of the article can be found here.
Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH acted as legal advisor to Proxygen. Dr Marco Stief and Dr Christian Pisani provided the legal advisory services.
